Skip to content

Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo

Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04374435
Enrollment
17
Registered
2020-05-05
Start date
2017-09-29
Completion date
2022-05-01
Last updated
2024-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Keywords

Vitiligo, Melanocyte, Keratinocyte, Transplantation, Procedure

Brief summary

Vitiligo is a dermatologic disease characterized by depigmentation of the skin. While the loss of melanocytes observed in vitiligo is driven by the immune system, repigmentation of the skin that occurs during UV light treatment is driven by melanocytes that migrate out of the hair follicle and into the epidermis or the activation of stem cells within the epidermis. Unfortunately, some skin areas affected by vitiligo have very few hair follicle melanocytes and an indeterminate number of epidermal melanocytes and therefore unable to respond to light therapy. This pilot study seeks to examine the relative efficacy of different harvesting methods for the melanocyte keratinocyte transplant procedure (MKTP) in the treatment of vitiligo. In addition, this study will analyze the tissue of excess tissue harvested during the procedure to identify distinct cellular and molecular features of chronic vitiligo. Patients in Dr. Ganesan's clinic at the UCI (University of California, Irvine) Department of Dermatology will be approached for participation in the study. The study will include both men and women and will not be limited by race or ethnicity. The investigators will exclude individuals less than 18 years old for the study as the investigators believe it would be difficult for these subjects to tolerate the melanocyte keratinocyte transplant procedure. Participants will be offered a melanocyte keratinocyte transplant procedure with one of the three different tissue harvesting methods (a blade, suction blister) and the method without dissociation (Cellutome). This study has three arms: 1. MKTP with Surgical Blade 2. MKTP with Negative Pressure Instrument (suction blistering device). 3. Suction blister grafting without cell dissociation utilizing Cellutome (a device used for treating chronic burn wounds)

Detailed description

In the first arm of the study, a normally pigmented area on the patient was anesthetized with 1% lidocaine with epinephrine. Using a surgical knife, the investigator removed a small portion of the epidermis that is unaffected by vitiligo from a small area (2cm2) on the patient's thigh to obtain donor cells. Epidermis that was harvested with the surgical knife was washed with Lactated Ringer's solution three times and then dissociated using trypsin to separate the cells into a single cell suspension. The recipient area to be grafted was ablated with an Erbium YAG(yttrium aluminum garnet)laser. Half of the dissociated single cells from the donor area (thigh)was then transplanted on to the area affected by vitiligo that the participant is interested in grafting (5 cm2 area). The investigator then evaluated response to treatment in the transplanted areas at 1 day, 1 week, 1 month and 3 months, and 6 months by both photography and quantifying the VASI(Vitiligo Area Scoring Index) score. VASI(Vitiligo Area Scoring Index)is the percentage of vitiligo involvement and is calculated in terms of hand units. One hand unit is approximately equivalent to 1% of the total body surface area. In the second arm of the study, the investigator used a minimally invasive procedure (suction blister grafting) to sample the grafted skin and donor skin- this method can separate the epidermis from the dermis without inducing a scar. A normally pigmented area on the upper thigh was anesthetized with 1% lidocaine with epinephrine. Using a suction blister technique, the investigator removed a small portion of the epidermis that was unaffected by vitiligo from a small area (4 cm2 or 0.6 inch cm2) on the patient's thigh to obtain donor cells. Epidermis that was harvested was washed with Lactated Ringer's solution three times and then dissociated using trypsin to separate the cells into a single cell suspension. The recipient areas to be grafted were used to harvest epidermis using a suction blister device. Half of the dissociated single cells from the donor area (thigh) were then transplanted on to the area affected by vitiligo that the patient was interested in grafting (5 cm2 area or 0.7 inch2). The suction blister skin from the recipient sites was simultaneously dissociated into a single cell suspension. A portion of the remainder of the cells (from both the donor and recipient site) was subjected to flow sorting to quantify the populations of melanocytes and keratinocytes and to detailed molecular analysis (single-cell RNA sequencing and histology) to characterize the molecular features of chronic vitiligo. The investigator then evaluated response to treatment in the transplanted areas at 1 day, 1 week, 1 month and 3 months, and 6 months by both photography and quantifying the VASI score. This arm of the study is complete. In the third arm of the study, the investigator uses a minimally invasive procedure (suction blister grafting without cell dissociation) to sample the grafted skin and donor skin- this method can separate the epidermis from the dermis without inducing a scar. A normally pigmented area on the upper thigh will be anesthetized with 1% lidocaine with epinephrine. Using an epidermal harvesting system which is a suction blister technique, the investigator will remove multiple small portions (about 128 blisters-1.8 mm in diameter) of the epidermis unaffected by vitiligo from a small normal area (5 cm2 ) on the patient's thigh to obtain donor cells and using a regular negative pressure instrument for removing four samples for histopathological study (two from the vitiligo area and two from the normal donor skin). The epidermis from the donor area (thigh) will then be transplanted on to the area affected by vitiligo that the patient is interested in grafting. Also, the four portions from the normal skin and the recipient site will be sent for the histopathological evaluation. The investigator will then evaluate response to treatment in the transplanted areas at 1 day, 1 week, 1 month and 3 months, and 6 months by both photography, quantifying the change in depigmented surface area, and the VASI(Vitiligo Area Scoring Index) score. Also, the investigator will evaluate the two vitiligo samples and two normal skin samples through histopathology to assess where the unique populations of cells identified in their RNA-sequencing analysis are localized (obtained from arm 2). The investigator hypothesizes that his transplant procedure will yield excellent to good repigmentation, resulting in a mean of 60% reduction in surface area (SD=30%) from baseline to 6-month follow up. With a sample size of 5 patients, this study will achieve 90% power to test this hypothesis based on a two-sided paired t-test at p=0.05 significance level. In addition, the investigator will compare the results from the 7 patients harvested using the surgical blade technique (procedure already completed and follow up results pending) with the results from 7 patients harvested with the suction blisters (completed) and seven patients from the newly proposed experimental group (three completed to date).

Interventions

PROCEDUREMKTP with Surgical blade

In this procedure, the donor skin will be harvested with a surgical blade and the donor skin will be dissociated

DEVICEMKTP with Negative Pressure Instrument

In this procedure, the investigator uses a negative pressure instrument to create a few blisters on the donor skin and use the blisters for grafting after cell dissociation.

DEVICESuction blister grafting without cell dissociation

In this procedure, an automated suction blister device will be used to create micro domes and these micro domes will be used directly for grafting without dissociation.

Sponsors

University of California, Irvine
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Masking description

The patients were not randomly assigned, rather each arm has been done sequentially with a retrospective comparison of the results.

Intervention model description

The investigators have completed two arms of the study in sequential study design (each arm has done individually with no random assignment). An exploratory third arm was initiated but then suspended.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Verified diagnosis of vitiligo by a board-certified dermatologist * Candidate for vitiligo treatment as determined by lead researcher * Has a 5 cm2 area of vitiligo and an area on the upper thigh that is not affected by the disease * Over 18 years of age at the time of signing the informed consent form * Ability to understand, abide by and participate in study procedures

Exclusion criteria

* Inability to understand or abide by instructions for participation in study and procedure * Pregnant or lactating women * Less than 18 years old at the time of signing the informed consent form * Current use of tobacco products or within 1 month prior to procedure date * History of coagulation disorder, platelet dysfunction disorder, platelet count less than \<150,000 platelets per microliter * History of poor wound healing or condition that would compromise optimal healing of graft site as deemed by lead researcher * History of keloids

Design outcomes

Primary

MeasureTime frameDescription
Number of Patients Who Had a Percent Change in Body Surface Area in Response Rate to Treatment6 monthsNumber of patients who had a percent change in body surface area in response rate to treatment as assessed by photography.
Change in VASI6 monthsPercent change in the transplanted areas as evaluated by VASI (Vitiligo Area Scoring Index). The negative scores mean improvement and positive scores means worsening.

Secondary

MeasureTime frameDescription
Percent of Patients That Healed in One Week6 monthsThe investigator will evaluate what percentage of patients healed at both the donor and graft site at one week.
Percentage of Patients That Experience Complications6 monthsThe investigator will record the percentage of patients that had complications in each group at either the donor or recipient site.

Countries

United States

Participant flow

Participants by arm

ArmCount
MKTP With Surgical Blade
The investigator harvested skin from the donor site and skin from the recipient site using a surgical blade in the first arm of the study. MKTP with Surgical blade: In this procedure, the donor skin will be harvested with a surgical blade and the donor skin will be dissociated
7
MKTP With Negative Pressure Instrument
Blister grafting technique with dissociation of the cells was performed in the second arm of the study. MKTP with Negative Pressure Instrument: In this procedure, the investigator uses a negative pressure instrument to create a few blisters on the donor skin and use the blisters for grafting after cell dissociation.
7
Suction Blister Grafting Without Cell Dissociation
In this arm, transplanting the blisters without dissociation of the cells will be conducted. Suction blister grafting without cell dissociation: In this procedure, an automated suction blister device will be used to create micro domes and these micro domes will be used directly for grafting without dissociation.
3
Total17

Baseline characteristics

CharacteristicMKTP With Surgical BladeMKTP With Negative Pressure InstrumentSuction Blister Grafting Without Cell DissociationTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants2 Participants2 Participants5 Participants
Age, Categorical
Between 18 and 65 years
6 Participants5 Participants1 Participants12 Participants
Age, Continuous47 years51 years52 years49 years
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants0 Participants0 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants5 Participants1 Participants11 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants2 Participants2 Participants5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
2 Participants7 Participants1 Participants10 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants0 Participants2 Participants4 Participants
Race (NIH/OMB)
White
3 Participants0 Participants0 Participants3 Participants
Region of Enrollment
United States
7 Participants7 Participants3 Participants17 Participants
Sex: Female, Male
Female
3 Participants6 Participants2 Participants11 Participants
Sex: Female, Male
Male
4 Participants1 Participants1 Participants6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 70 / 3
other
Total, other adverse events
0 / 70 / 70 / 3
serious
Total, serious adverse events
0 / 70 / 70 / 3

Outcome results

Primary

Change in VASI

Percent change in the transplanted areas as evaluated by VASI (Vitiligo Area Scoring Index). The negative scores mean improvement and positive scores means worsening.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
MKTP With Surgical BladeChange in VASI-23.0 % change in vitiligo surface areaStandard Deviation 24
MKTP With Negative Pressure InstrumentChange in VASI-10.2 % change in vitiligo surface areaStandard Deviation 18.9
Suction Blister Grafting Without Cell DissociationChange in VASI-0.33 % change in vitiligo surface areaStandard Deviation 0.35
Primary

Number of Patients Who Had a Percent Change in Body Surface Area in Response Rate to Treatment

Number of patients who had a percent change in body surface area in response rate to treatment as assessed by photography.

Time frame: 6 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
MKTP With Surgical BladeNumber of Patients Who Had a Percent Change in Body Surface Area in Response Rate to Treatment6 Participants
MKTP With Negative Pressure InstrumentNumber of Patients Who Had a Percent Change in Body Surface Area in Response Rate to Treatment4 Participants
Suction Blister Grafting Without Cell DissociationNumber of Patients Who Had a Percent Change in Body Surface Area in Response Rate to Treatment2 Participants
Secondary

Percentage of Patients That Experience Complications

The investigator will record the percentage of patients that had complications in each group at either the donor or recipient site.

Time frame: 6 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
MKTP With Surgical BladePercentage of Patients That Experience Complications0 Participants
MKTP With Negative Pressure InstrumentPercentage of Patients That Experience Complications0 Participants
Suction Blister Grafting Without Cell DissociationPercentage of Patients That Experience Complications0 Participants
Secondary

Percent of Patients That Healed in One Week

The investigator will evaluate what percentage of patients healed at both the donor and graft site at one week.

Time frame: 6 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
MKTP With Surgical BladePercent of Patients That Healed in One Week7 Participants
MKTP With Negative Pressure InstrumentPercent of Patients That Healed in One Week7 Participants
Suction Blister Grafting Without Cell DissociationPercent of Patients That Healed in One Week3 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026